Rafferty Asset Management’s Janux Therapeutics JANX Stock Holding History

Rafferty Asset Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$823K	Sell	53,608 -22,124	-29%	-$320K	﹤0.01%	822
2026 Q1	$1.05M	Sell	75,732 -99,516	-57%	-$1.36M	﹤0.01%	753
2025 Q4	$2.42M	Buy	175,248 +99,052	+130%	+$2.33M	0.01%	608
2025 Q3	$1.86M	Buy	76,196 +29,267	+62%	+$713K	0.01%	660
2025 Q2	$1.08M	Sell	46,929 -9,350	-17%	-$246K	﹤0.01%	750
2025 Q1	$1.52M	Buy	56,279 +4,111	+8%	+$155K	0.01%	649
2024 Q4	$2.79M	Sell	52,168 -13,522	-21%	-$715K	0.01%	546
2024 Q3	$2.98M	Sell	65,690 -11,556	-15%	-$503K	0.01%	538
2024 Q2	$3.24M	Buy	+77,246	New	+$3.63M	0.01%	512

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Rafferty Asset Management's JANX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Janux Therapeutics (JANX) stake by 29% in Q2 2026, selling an estimated $320K and leaving 53,608 shares worth $823K. The position accounts for ﹤0.01% of the portfolio, ranked #822.

Rafferty Asset Management first reported a position in JANX in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.24M in Q2 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Rafferty Asset Management held 53,608 shares of Janux Therapeutics worth $823K as of Q2 2026.
Rafferty Asset Management sold 22,124 Janux Therapeutics shares in Q2 2026, an estimated $320K.
Janux Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #822 holding.
Rafferty Asset Management first reported a position in Janux Therapeutics in Q2 2024 and has held it in 9 quarters since.
Rafferty Asset Management's Janux Therapeutics position peaked at $3.24M in Q2 2024.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.